Adrenomedullin antagonist suppresses tumor formation in renal cell carcinoma through inhibitory effects on tumor endothelial cells and endothelial progenitor mobilization
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Adrenomedullin (AM) is a multifunctional 52-amino acid peptide. AM has several effects and acts as a growth factor in several types of cancer cells. Our previous study revealed that an AM antagonist (AMA) suppressed the growth of pancreatic tumors in mice, although its mechanism was not elucidated. In this study, we constructed an AMA expression vector and used it to treat renal cell carcinoma (RCC) in mice. This AMA expression vector significantly reduced tumor growth in mice. In addition, microvessel density was decreased in AMA-treated tumors. To analyze the effect of AMA on tumor angiogenesis in this model, tumor endothelial cells (TECs) were isolated from RCC xenografts. TEC proliferation was stimulated by AM and it was inhibited by AMA significantly. AM induced migration of TECs and it was also blocked by AMA. However, normal ECs (NECs) were not affected by either AM or AMA. These results demonstrate that AMA has inhibitory effects on TECs specifically, not on NEC, thereby inhibiting tumor angiogenesis. Furthermore, we showed that vascular endothelial growth factor-induced mobilization of endothelial progenitor cell (EPC) into circulation was inhibited by AMA. These results suggest that AMA can be considered a good anti-angiogenic reagent that selectively targets TECs and EPC in renal cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lyden, D., Hattori, K., Dias, S., Costa, C., Blaikie, P., Butros, L., Chadburn, A., Heissig, B., Marks, W., Witte, L., et al. (2001) · Nature Medicine · doi:10.1038/nm1101-1194 · Cited by 1,860 · cited 2×
“It has been shown that tumors mobilize bone marrow-derived EPCs, besides recruiting neighboring blood vessels or ECs, and that EPCs migrate to tumors and become incorporated into their developing vasculature (30).”
Cited by
Gonzalez-Avila, G., Sommer, B., Mendoza-Posada, D. A., Ramos, C., Garcia-Hernandez, A. A., & Falfan-Valencia, R. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.02.010 · Cited by 373
Contribution of Tumor Endothelial Cells in Cancer Progression
Hida, K., Maishi, N., Annan, D., & Hida, Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051272 · Cited by 259
Endothelial Cells in the Tumor Microenvironment
Sobierajska, K., Ciszewski, W. M., Sacewicz-Hofman, I., & Niewiarowska, J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-37184-5_6 · Cited by 179
Akiyama, K., Ohga, N., Hida, Y., Kawamoto, T., Sadamoto, Y., Ishikawa, S., Maishi, N., Akino, T., Kondoh, M., Matsuda, A., et al. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.11.029 · Cited by 154
Tumour endothelial cells acquire drug resistance in a tumour microenvironment
Hida, K., Akiyama, K., Ohga, N., Maishi, N., & Hida, Y. (2013) · Journal of Biochemistry · doi:10.1093/jb/mvs152 · Cited by 68
Metadata
- Authors
- Hida
- Venue
- International Journal of Oncology
- Publisher
- Spandidos Publications
- Published
- 2010-04-21
- Volume
- 36
- Issue
- 6
- Pages
- 1379-86
- ISSN
- 1019-6439 (ISSN-L)
- 1791-2423
- OpenAlex
- W2165986772
- Cited by
- 50
- References
- 1
- FWCI
- 2.36
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.